- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00852956
Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects
This will be a phase I, randomized, two-arm, double-blind, placebo-controlled, sequential study in up to 50 healthy female subjects. The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:
Period I 1 week (Days 1-7) administration of betahistine daily (three times per day; 144 mg/day total) or matching placebo.
Period II 1 week (Days 8-14) titration of olanzapine once daily (2.5 to 10 mg) and continuation of betahistine or matching placebo administration (daily; three times per day) Period III 2 weeks (Days 15-28) of continued co-administration of betahistine/matching placebo, three times per day, and olanzapine once daily (7.5 to 10 mg/day)
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Arad, Romania
- IFE Human Pharmacology
-
Timisoara, Romania
- IFE Human Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy female subjects 18 to 45 years of age.
- Signed written informed consent.
- Willing and able to comply with study procedures (including staying overnight in the research facility for required period for PK sampling).
- Regular menstrual period.
- All subjects should be non-lactating, have a negative urine pregnancy test result, and do not plan on become pregnant during the study, must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.
Has been on a stable treatment regimen with any of the following medications for a minimum of 90 days prior to screening:
- Hormone replacement therapy;
- Oral contraceptives.
Exclusion Criteria:
- Has abnormal body composition, either overweight or obesity (BMI > 27 Kg/m2) or undernourishment (BMI < 18.5 Kg/m2).
- Has had a significant body weight loss of >4 kg in the 90 days prior to screening.
- Pregnancy or lactation.
- Has recently started a smoking cessation program.
- Has known sensitivity to betahistine or olanzapine.
- Having first degree relatives with diabetes.
- Personal history of gestational diabetes.
- Subjects diagnosed with polycystic ovary disease.
Has a clinically significant history or presence of any of the following conditions:
- Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities
- Diabetes mellitus (type 1 or 2)
- Fasting blood glucose level > 100 mg/dL or HBA1c > 6.0% at screening.
- Renal insufficiency defined as a serum creatinine >1.5 mg/dL (133 µmol/L) at screening
- Malignant disease within 5 years of screening
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 ULN
- Thyroid-stimulating hormone (TSH) outside of the normal range
- Plans on having any surgery (elective or otherwise) during the course of the study
- Has hypertension (sitting blood pressure >140/90 mmHg at screening or randomization),
- Has hyperlipidemia (triglycerides [TG] >200 mg/dL or low-density lipoprotein cholesterol [LDL-C] >190 mg/dL),
- History of asthma
- History of peptic ulcers
- History of HIV, Hepatitis B, Hepatitis C
- Has clinical laboratory test values (chemistry, hematology, metabolic or urinalysis) judged to be clinically significant by the investigator
- Has a physical examination or electrocardiogram (ECG) with significant abnormalities, as judged by the investigator
- Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion could cause the subject to be noncompliant with study procedures
- Has psychiatric or neurological disorders requiring chronic medications (e.g., antidepressants, anti-psychotic or anti anxiety agents).
- Chronic or as needed use of antihistamines
- Has been treated over the past 60 days, is currently treated, or is expected to require or undergo treatment with any medications for a period of more than 3 days (with the exception of antibiotic treatment for a period of less than 7 days).
- Has received any investigational drug within 90 days prior to screening.
- Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or is employed by OBEcure Ltd.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
|
The study will be comprised of three treatment periods for a total of 4 weeks treatment duration: Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated) On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio: Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00 |
Active Comparator: Control
Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
|
The study will be comprised of three treatment periods for a total of 4 weeks treatment duration: Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated) On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio: Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objectives are to evaluate the safety, tolerability, pharmacokinetic profiles and drug-drug interactions of betahistine and olanzapine at steady-state in healthy female subjects.
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBE 209
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Betahistine
-
OBEcure Ltd.International Antiviral Therapy Evaluation CenterCompletedObesityBelgium, Germany, Netherlands
-
Eunice Kennedy Shriver National Institute of Child...CompletedObesity | Overnutrition | OverweightUnited States
-
P2D, Inc.National Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Abbott ProductsCompletedGait or Balance Disorder ProblemsSingapore
-
University of CincinnatiTerminatedRecurrent Major Depressive Disorder With Atypical FeaturesUnited States
-
OBEcure Ltd.Completed
-
Beijing Tongren HospitalCompleted
-
Seoul National University HospitalRecruitingMeniere's DiseaseKorea, Republic of
-
Solvay PharmaceuticalsCompleted
-
Neuro Counsel Hospital, PakistanCompletedBenign Paroxysmal Positional VertigoPakistan